Evaluation of the effectiveness of Boswellia serrata in the treatment of psoriasis

Evaluation of the effectiveness of topical formulation of Boswellia serrata extract compared to clobetasol in the treatment of psoriasis vulgaris; a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150721023282N23

Enrollment

Registered

2022-09-13

Start date

2022-12-21

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis vulgaris. Psoriasis vulgaris

Interventions

Intervention 1: Intervention group: 10% boswellia Ointment, made by Isfahan University of Medical Science, School of Pharmacy,twice a day, for 28 days. Intervention 2: Control group: 0.05% clobetasol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mild psoriasis vulgaris in the areas of limbs and trunk; Mild psoriasis is defined as Involvement of a maximum of 10% of the body surface area (BSA).

Exclusion criteria

Exclusion criteria: Incidence of other types of psoriasis (erythrodermic, guttate, ...) Incidence of Facial or scalp psoriasis Incidence of psoriatic arthritis Receiving systemic anti-psoriasis treatment and phototherapy during last month Receiving topical anti-psoriasis treatment during last two weeks Autoimmune disorders Incidence of other chronic skin disorders (pemphigus, eczema, dermatitis, lichen planus) Infection in the lesion Pregnancy Lactation

Design outcomes

Primary

Measure	Time frame
Change in Psoriasis Area and Severity Index (PASI) Before the intervention and at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: The online calculator that is available on the following website: https://www.mdcalc.com/calc/10182/psoriasis-area-severity-index-pasi.;Percentage change in body surface area (BSA) at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: chart.	—

Measure

Time frame

Change in Psoriasis Area and Severity Index (PASI) Before the intervention and at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: The online calculator that is available on the following website: https://www.mdcalc.com/calc/10182/psoriasis-area-severity-index-pasi.;Percentage change in body surface area (BSA) at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: chart.

—

Secondary

Measure	Time frame
Intensity of itching. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Use Visual Analogue Scale (VAS) from 0 (No itchy) to 10 (Extremely itchy) by patients.;Proportion of people with PASI 50 (decrease of at least 50% in the PASI score) at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Observation.;Proportion of people with complete recovery (PASI 90) at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Observation.	—

Measure

Time frame

Intensity of itching. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Use Visual Analogue Scale (VAS) from 0 (No itchy) to 10 (Extremely itchy) by patients.;Proportion of people with PASI 50 (decrease of at least 50% in the PASI score) at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Observation.;Proportion of people with complete recovery (PASI 90) at the end of the intervention. Timepoint: Before the intervention, 28 days after the start of intervention. Method of measurement: Observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasool Soltani

Esfahan University of Medical Sciences

soltani@pharm.mui.ac.ir+98 31 3792 7067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026